EUVIMEDEUVIMED entdecken
Validierungsstudie

Identification and Validation of Rhizopus -Specific Glucoamylase as a Novel Biomarker for Diagnosing Mucormycosis

Hansraj Choudhary, Harsimran Kaur iD, Shreya Singh, Rachna Singh iD, Valliappan Muthu iD, Roshan Verma, Shivaprakash M Rudramurthy, Ritesh Agarwal, Sanjay Jain iD, Amanjit Bal iD, Anup Ghosh iD, Arunaloke Chakrabarti iD

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag126 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Hansraj Choudhary und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Mucormycosis, Rhizopus, Glucan 1,4-alpha-Glucosidase, Antigens, Fungal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Indian Council of Medical Research (ICMR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mucormycosis is a life-threatening invasive fungal infection. Current diagnosis relies on insensitive techniques with prolonged turnaround times, underscoring the need for rapid noninvasive diagnostic tools. The current study aimed to identify the antigens of Rhizopus arrhizus that can facilitate serodiagnosis of mucormycosis and assess their diagnostic potential in patients.

Methods

This was a 2-stage systematic study combining antigen discovery and clinical validation. Using immunoproteomics, we identified immunoreactive protein spots in R. arrhizus secretory extract, using pooled serum samples from 6 patients with mucormycosis. We performed liquid chromatography–tandem mass spectrometry (LC-MS/MS) to characterize the most reactive spot. Next, we developed an indirect enzyme-linked immunosorbent assay using purified protein and evaluated its diagnostic performance in 92 patients with mucormycosis and 41 controls (22 with other mold infections and 19 with diabetes mellitus alone). Participants were randomly divided 1:1 into derivation and validation cohorts. Receiver operating characteristic curve analysis identified optimal cutoff values.

Results

Immunoproteomics identified 3 immunoreactive protein spots (70, 45, and 30 kDa) in crude extract. The most reactive 70-kDa spot was identified as Rhizopus-specific glucoamylase (RSG) by LC-MS/MS and confirmed with specific anti-Rhizopus glucoamylase antibody. In the derivation cohort (46 patients with mucormycosis and 11 controls), the area under the receiver operating characteristic curve for anti-RSG immunoglobulin (Ig) G was 0.933. In the validation cohort, anti-RSG IgG achieved 76.1% sensitivity (95% confidence interval, 61.2%–87.4%) and 100% specificity (71.5%–100%). The assay also detected antibodies in 85.1% of culture-negative but microscopy-positive cases and in 87.5% of mixed fungal infection cases.

Conclusions

RSG is a potential biomarker for diagnosing mucormycosis. Anti-RSG IgG shows strong diagnostic promise and merits prospective multicenter clinical validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucormycosisRhizopusGlucan 1,4-alpha-GlucosidaseAntigens, FungalHumansBiomarkersFemaleMaleAdultMiddle AgedTandem Mass SpectrometryEnzyme-Linked Immunosorbent AssaySensitivity and SpecificityROC CurveSerologic TestsAgedAntibodies, Fungal

Stichwörter der Autor:innen

Rhizopus-specific glucoamylase; ELISAbiomarkermucormycosisserodiagnosis

Substanzen

BiomarkersGlucan 1,4-alpha-GlucosidaseAntigens, FungalAntibodies, Fungal

Autor:innen und Institutionen

  • Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.
  • Division of Communicable Diseases, Indian Council of Medical Research (ICMR), New Delhi, India.
  • Department of Medical Parasitology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.
  • Department of Microbial Biotechnology, Panjab University, Chandigarh, India.
  • Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research, (PGIMER), Chandigarh, India.
  • Department of Otolaryngology, Head and Neck Surgery, Postgraduate Institute of Medical Education & Research, (PGIMER), ChandigarhIndia.

ORCID-Profile: Harsimran Kaur, Rachna Singh, Valliappan Muthu, Sanjay Jain, Amanjit Bal, Anup Ghosh, Arunaloke Chakrabarti

Förderung

  • Indian Council of Medical Research (ICMR)

Zitieren

APA

Choudhary, H., Kaur, H., Singh, S., Singh, R., Muthu, V., Verma, R., Rudramurthy, S. M., Agarwal, R., Jain, S., Bal, A., Ghosh, A., & Chakrabarti, A. (2026). Identification and Validation of Rhizopus -Specific Glucoamylase as a Novel Biomarker for Diagnosing Mucormycosis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag126

Vancouver

Choudhary H, Kaur H, Singh S, Singh R, Muthu V, Verma R, et al. Identification and Validation of Rhizopus -Specific Glucoamylase as a Novel Biomarker for Diagnosing Mucormycosis. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag126

BibTeX
@article{Choudhary2026,
  author = {Choudhary, Hansraj and Kaur, Harsimran and Singh, Shreya and Singh, Rachna and Muthu, Valliappan and Verma, Roshan and Rudramurthy, Shivaprakash M and Agarwal, Ritesh and Jain, Sanjay and Bal, Amanjit and Ghosh, Anup and Chakrabarti, Arunaloke},
  title = {Identification and Validation of Rhizopus -Specific Glucoamylase as a Novel Biomarker for Diagnosing Mucormycosis},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag126}
}
Kostenlos starten →